Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Pipeline Review, H1 2016
Summary
Global Markets Direct’s, ‘Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Pipeline Review, H1 2016’, provides in depth analysis on Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) targeted pipeline therapeutics.
The report provides comprehensive information on the Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - The report reviews Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) targeted therapeutics and enlists all their major and minor projects - The report assesses Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
2021 Vitamins and Herbal Dietary Supplement Market - Size, Share, COVID Impact Analysis and Forecast to 2027 2021 Vitamins and Herbal Dietary Supplement Market - Size, Share, COVID Impact Analysis and Forecast to 2027 – is comprehensive research with in-depth data and contemporary analysis of Vitamins and Herbal Dietary...
90 pages •
By Euromonitor International
• Nov 2020
Consumer health is expected to see slightly higher current value growth in 2020 than was seen in 2019, with COVID-19 expected to be one of the main factors dictating growth in Uruguay. While the COVID-19 outbreak in Uruguay had little impact in terms of infections and deaths due to the country’s good healthcare system, locals’ concern about...
90 pages •
By Euromonitor International
• Nov 2020
The first cases of COVID-19 in Belarus were recorded on 27 February 2020 and, in June 2020, Belarus continued to record nearly 800 cases of COVID-19 daily. Stockpiling occurred in mid-March 2020, with COVID-19 driving demand for analgesics, cough, cold and allergy (hay fever) remedies, vitamins and dietary supplements. No quarantine took place...
88 pages •
By Euromonitor International
• Nov 2020
During the COVID-19 pandemic, Georgian consumer health faced further regulations and limits on volume sales. The sales of masks and sanitizing products and equipment, for example, was limited in order to prevent stockpiling and ensure continued availability of these products.
Consumer Health in Georgia report offers a comprehensive...
92 pages •
By Euromonitor International
• Oct 2020
COVID-19 will not have a significant impact on growth in current retail value sales of consumer health in Bosnia and Herzegovina during 2020. Neither stockpiling nor significant product shortages have been reported. Moreover, the income elasticity of demand for many consumer health products is quite low, so the economic slowdown provoked by...
The women’s health diagnostics market is projected to reach USD 36.6 billion by 2025 from USD 25.0 billion in 2020, at a CAGR of 7.9% during the forecast period. In the past decade, the demand for various health diagnostic tests has increased significantly across the globe. Currently, the market is mainly driven by growing awareness about...
94 pages •
By Euromonitor International
• Nov 2020
With Kenyans mired in the COVID-19 pandemic, it is perhaps not surprising that value sales of consumer health products are set to rise in 2020 at a rate higher than those recorded during the review period. Broadly, a pandemic-inspired heightened focus on maintaining/improving health is driving greater interest in over the counter (OTC) health...
91 pages •
By Euromonitor International
• Nov 2020
The main developments in consumer health in Costa Rica in 2020 as a result of COVID-19 are related to the sudden spike in the sales of vitamins and dietary supplements, particularly those associated to immunity responses. For example, echinacea has gained significant awareness amongst local consumers in 2020. COVID-19 resulted in shortages...
88 pages •
By Euromonitor International
• Nov 2020
Consumer health is expected to see much higher current value growth in 2020 than was seen the previous year. One of the factors dictating growth in this year is expected to be COVID-19. As news about the virus emerged in the country, consumers began panic-buying at the beginning of March, stockpiling certain consumer health products, such...
85 pages •
By Euromonitor International
• Nov 2020
The COVID-19 pandemic is not having the same drastic impact on consumer health as seen with other industries in 2020. The industry has been allowed to continue its operations because it produces and sells necessity products, some of which have increased in demand in response to the outbreak of the virus. Likewise, the key retail distributors...
OTC
Dietary Supplement
Vitamin
Guatemala
Analgesic Medicine Sales
Vitamin Sales
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.